Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 555-556, 2006; 10.1373/clinchem.2005.065284
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peters, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, T., Jr
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2006;52:555-556.)
© 2006 American Association for Clinical Chemistry, Inc.

Editorials

How Should We Measure the Albumin in Urine?

Theodore Peters, Jr

Research Institute The Mary Imogene Bassett Hospital Cooperstown, NY 13326 Fax 607-547-3061 E-mail theodore.peters@bassett.org

The first 20% of the full text of this article appears below.

Laboratories almost universally use immunochemical methods to detect microalbuminuria, defined variously as an albumin excretion of 30–300 mg/day, an albumin/creatinine ratio of 30–300 mg/g, or an albumin excretion rate of 20–200 µg/min. (The term microalbuminuria is a misnomer, of course. No small form of albumin exists that is comparable, for example, to ß2-microglobulin, but the term now seems too deeply imbedded in the diabetic literature to be replaced.)

During the last 3 years, size-exclusion HPLC has been promoted to detect forms of albumin that are not reactive immunochemically (1)(2). The authors of these studies claimed that this approach is more sensitive in detecting increases in urinary albumin and detects them earlier than do the immunochemical methods (3). They isolated this nonimmunoreactive albumin form after adsorption on immobilized anti-albumin and found that it contained <1% of the potential contaminants transferrin, {alpha}1-acid glycoprotein, and {alpha}1-antitrypsin by immunochemical tests and little, if any, by mass spectrometry.

A challenge to these findings appeared in the . . . [Full Text of this Article]


Preconcentration of urines.


Number of samples.


Contaminating plasma proteins.


Application of other techniques.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. Sviridov, S. K. Drake, and G. L. Hortin
Reactivity of Urinary Albumin (Microalbumin) Assays with Fragmented or Modified Albumin
Clin. Chem., January 1, 2008; 54(1): 61 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
O. T.M. Chan and D. A. Herold
Chip Electrophoresis as a Method for Quantifying Total Microalbuminuria
Clin. Chem., November 1, 2006; 52(11): 2141 - 2146.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.